Advertisement

Digestive Diseases and Sciences

, Volume 53, Issue 11, pp 2896–2903 | Cite as

An Open-Labeled Study of Rebamipide Treatment in Chronic Gastritis Patients with Dyspeptic Symptoms Refractory to Proton Pump Inhibitors

  • Taned Chitapanarux
  • Ong-ard Praisontarangkul
  • Nirush Lertprasertsuke
Original Paper

Abstract

To assess the efficacy of rebamipide therapy in chronic gastritis patients with refractory dyspeptic symptoms, we enrolled 30 patients with chronic gastritis nonresponsive to the antisecretory medications, proton pump inhibitors. Upper gastrointestinal endoscopy was performed in all patients to confirm and evaluate the severity of gastritis by gastric mucosal injury score and the histology by the updated Sydney system before and after treatment with rebamipide 300 mg daily for 8 weeks. At the end of the study, significant improvement in the scores for symptoms (epigastralgia, stomach heaviness, and abdominal fullness) and endoscopic mucosal injury were observed for all patients. The degrees of neutrophil activity in antrum and mononuclear cell inflammation in both body and antrum significantly decreased from baseline. Improvement of gastritis might be the mechanism by which rebamipide prevents gastric mucosal inflammation. In conclusion, rebamipide treatment improved symptom, endoscopic, and histologic features of chronic gastritis in patients with refractory dyspeptic symptoms.

Keywords

Rebamipide Proton pump inhibitor Gastritis Dyspepsia  

References

  1. 1.
    Atisook K, Kachinthorn U, Luengrojanakul P, Tanwandee T, Pakdirat P, Puapairoj A (2003) Histology of gastritis and Helicobacter pylori infection in Thailand: a nationwide study of 3776 cases. Helicobacter 8:132–141. doi: 10.1046/j.1523-5378.2003.00134.x PubMedCrossRefGoogle Scholar
  2. 2.
    Hojgaard L, Matzen P, Christofferson P (1987) Gastritis—a clinical entity? Scand J Gastroenterol Suppl 128:90–93. doi: 10.3109/00365528709090974 PubMedCrossRefGoogle Scholar
  3. 3.
    Elta GH, Appelman HD, Behler EM, Wilson JA, Nostrant TJ (1987) A study of the correlation between endoscopic and histological diagnoses in gastroduodenitis. Am J Gastroenterol 82:749–753PubMedGoogle Scholar
  4. 4.
    Boyko DA, Flind AC, Guslandi M (1986) Non-ulcer dyspepsia. Lancet 328:113. doi: 10.1016/S0140-6736(86)91651-X CrossRefGoogle Scholar
  5. 5.
    Chey WD, Wong BC (2007) Practice parameters committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808–1825. doi: 10.1111/j.1572-0241.2007.01393.x PubMedCrossRefGoogle Scholar
  6. 6.
    Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181–202. doi: 10.1517/phgs.5.2.181.27483 PubMedCrossRefGoogle Scholar
  7. 7.
    Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res 52:6735–6740PubMedGoogle Scholar
  8. 8.
    Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, Fujii T, Yoshida N, Kondo M, Sasaki E (1998) Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in double-blind, placebo-controlled study. Dig Dis Sci 43:83S–89SPubMedGoogle Scholar
  9. 9.
    Nebiki H, Higuchi K, Arakawa T, Ando K, Uchida T, Ito H, Harihara S, Kuroki T, Kobayashi K (1998) Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. Dig Dis Sci 43:203S–206S. doi: 10.1023/A:1018813229334 PubMedCrossRefGoogle Scholar
  10. 10.
    Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K (1992) Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung 42:1462–1466PubMedGoogle Scholar
  11. 11.
    Song DU, Ryu MH, Chay KO, Jung YD, Yang SY, Cha SH, Lee MW, Ahn BW (1998) Effect of rebamipide on glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol 12:546–552PubMedCrossRefGoogle Scholar
  12. 12.
    Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S (1987) Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 142:23–29. doi: 10.1016/0014-2999(87)90649-2 PubMedCrossRefGoogle Scholar
  13. 13.
    Kleine A, Kluge S, Peskar BM (1993) Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441–1449. doi: 10.1007/BF01308601 PubMedCrossRefGoogle Scholar
  14. 14.
    Ogino K, Hobara T, Ishiyama H, Yamasaki K, Kobayashi H, Izumi Y, Oka S (1992) Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyl-dithiocarbamate-induced antral gastric ulcers in rats. Eur J Pharmacol 212:9–13. doi: 10.1016/0014-2999(92)90065-C PubMedCrossRefGoogle Scholar
  15. 15.
    Suzuki M, Miura S, Mori M, Kai A, Suzuki H, Fukumura D, Suematsu M, Tsuchiya M (1994) Rebamipide, a novel anti-ulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 35:1375–1378. doi: 10.1136/gut.35.10.1375 PubMedCrossRefGoogle Scholar
  16. 16.
    Yoshikawa T, Naito Y, Tanigawa T, Kondo M (1993) Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 43:363–366PubMedGoogle Scholar
  17. 17.
    Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M (1995) Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18:117–123. doi: 10.1016/0891-5849(94)00110-6 PubMedCrossRefGoogle Scholar
  18. 18.
    Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (1998) Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43 [Suppl 9]:5S–13SPubMedGoogle Scholar
  19. 19.
    Hiquchi K, Arakawa T, Nebiki H, Uchida T, Fujiwara Y, Ando K, Yamasaki K, Takaishi O, Fukuda T, Kobayashi K, Kuroki T (1998) Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci 43 [Suppl]:S99–S106Google Scholar
  20. 20.
    Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Samii M, Tanaka S, Yoshihara M, Chayama K (2002) Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci 47:862–867. doi: 10.1023/A:1014716822702 PubMedCrossRefGoogle Scholar
  21. 21.
    Karvonen AL, Sipponen P, Lehtola J, Ruokonen A (1983) Gastric mucosal erosions. An endoscopic, histologic, and functional study. Scand J Gastroenterol 18:1051–1056PubMedCrossRefGoogle Scholar
  22. 22.
    Miehlke S, Hackelsberger A, Meining A, Hatz R, Lehn N, Malfertheiner P, Stolte M, Bayerdörffer E (1988) Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 78:263–266CrossRefGoogle Scholar
  23. 23.
    Fiocca R, Villani L, Luinetti O, Gianatti A, Perego M, Alvisi C, Turpini F, Solcia E (1992) Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer; a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol 420:489–498PubMedCrossRefGoogle Scholar
  24. 24.
    Stolte M, Eidt S (1992) Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis. Z Gastroenterol 30:846–850. doi: 10.1007/BF01600253 Google Scholar
  25. 25.
    Gallo N, Zambon CF, Navaglia F, Basso D, Guariso G, Grazia Piva M, Greco E, Mazza S, Fogar P, Rugge M, Di Mario F, Plebani M (2003) Helicobacter pylori infection in children and adults: a single pathogen but a different pathology. Helicobacter 8:21–28. doi: 10.1046/j.1523-5378.2003.00120.x PubMedCrossRefGoogle Scholar
  26. 26.
    Yamamura F, Yoshikawa N, Akita Y, Mitamura K, Miyasaka N (1999) Relationship between Helicobacter pylori infection and histologic features of gastritis in biopsy specimens in gastroduodenal diseases, including evaluation of diagnosis by polymerase chain reaction assay. J Gastroenterol 34:461–466. doi: 10.1007/s005350050297 PubMedCrossRefGoogle Scholar
  27. 27.
    Kamada T, Suqiu K, Hata J, Kusunoki H, Hamada H, Kido S, Naqashima Y, Kawamura Y, Tanaka S, Chayama K, Haruma K (2006) Evaluation of endoscopic and histological findings in Helicobacter pylori-positive Japanese young adult. J Gastroenterol Hepatol 21:258–261. doi: 10.1111/j.1440–1746.2006.04128.x PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang C, Yamada N, Wu YL, Wen M, Matsuhisa T, Matsukura N (2005) Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients. World J Gastroenterol 11:976–981PubMedGoogle Scholar
  29. 29.
    Talley NJ, Riff DS, Schwartz H, Marcuard SP (2001) Double-blind placebo-controlled multicenter studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther 15:1603–1611. doi: 10.1046/j.1365-2036.2001.01074.x PubMedCrossRefGoogle Scholar
  30. 30.
    Miwa H, Osada T, Nagahara A, Ohkusa T, Hojo M, Tomita T, Hori K, Matsumoto T, Sato N (2006) Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol 21:1826–1831. doi: 10.1111/j.1440-1746.2006.04446.x PubMedCrossRefGoogle Scholar
  31. 31.
    Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, Higuchi K, Haruma K, Murakami K, Kobayashi K (2007) Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following therapy for Helicobacter pylori in Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 42:690–693. doi: 10.1007/s00535-007-2076-2 PubMedCrossRefGoogle Scholar
  32. 32.
    Kim HK, Kim JI, Kim JK, Han JY, Park SH, Choi KY, Chung IS (2007) Preventive effect of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 52:1776–1782. doi: 10.1007/s10620-006-9367-y PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Taned Chitapanarux
    • 1
  • Ong-ard Praisontarangkul
    • 1
  • Nirush Lertprasertsuke
    • 2
  1. 1.Department of Medicine, Division of Gastrohepatology, Faculty of MedicineChiang Mai UniversityChiang MaiThailand
  2. 2.Department of Pathology, Faculty of MedicineChiang Mai UniversityChiang Mai 50200Thailand

Personalised recommendations